Sparfloxacin
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Sparfloxacin: From Unknown Original Indication to Hyperamylasemia
One-Sentence Summary
Sparfloxacin is a fluoroquinolone-class antibacterial agent (inhibiting bacterial DNA gyrase/topoisomerase IV per class knowledge); its specific original approved indication is not captured in this evidence pack. The TxGNN model predicts it may be effective for Hyperamylasemia, but this is a model-only prediction (L5) — the evidence pack itself notes no clinical trials, no literature, and no plausible mechanistic link, and flags the signal as possibly reflecting knowledge-graph node proximity rather than real biology.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in this pack (Data Gap); known generically as a fluoroquinolone-class antibacterial |
| Predicted New Indication | Hyperamylasemia |
| TxGNN Prediction Score | 99.74% |
| Evidence Level | L5 (model prediction only, no supporting trials/literature, no mechanistic link) |
| Taiwan Market Status | Not marketed (Not marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (original_moa is a Data Gap in this pack). Based on other fields in the evidence pack, Sparfloxacin is described as a fluoroquinolone-class antibiotic that inhibits bacterial DNA gyrase/topoisomerase IV — a mechanism relevant to treating bacterial infections, not to metabolic/enzymatic conditions like hyperamylasemia.
For the top-ranked prediction, the pack’s own rationale is explicit: “無明確機轉關聯。Hyperamylasemia 多與胰臟/唾液腺病理相關，抗生素類藥物無已知直接作用路徑，此預測可能反映知識圖譜節點鄰近性而非真實生物學訊號” — i.e., there is no known biological pathway connecting a DNA gyrase inhibitor to pancreatic/salivary-gland amylase overproduction, and the high TxGNN score likely reflects graph topology rather than pharmacology.
Notably, among the 9 ranked candidates in this pack, only septicemic plague (rank 8) has class-level mechanistic plausibility — other fluoroquinolones (ciprofloxacin, levofloxacin) are approved for Yersinia pestis infection, and one loosely related PMID (antibiotic persistence in uropathogenic E. coli) was retrieved — though no sparfloxacin-specific evidence exists there either. This does not change the assessment of the rank-1 candidate (hyperamylasemia), which remains mechanistically unsupported.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Taiwan Market Information
No marketing authorizations are registered for Sparfloxacin in Taiwan (market status: Not marketed / not marketed; total licenses: 0).
Safety Considerations
Drug Interactions: The evidence pack contains 239 recorded interactions. Major-severity interactions identified include:
| Interacting Drug | Level | Source |
|---|---|---|
| Hydrocortisone | Major | ddinter |
| Bupropion | Major | ddinter |
| Triamcinolone | Major | ddinter |
| Dexamethasone | Major | ddinter |
| Betamethasone | Major | ddinter |
| Chlorpropamide | Major | ddinter |
Additional Moderate-level interactions (partial list, 239 total recorded): Acarbose, Famotidine, Albiglutide, Alogliptin, Metformin, Pioglitazone, Loperamide, Acetylsalicylic acid, Balsalazide, Bisacodyl, Calcium Phosphate, Calcium acetate, Canagliflozin, Potassium citrate.
Key warnings and contraindications for Sparfloxacin are not available in this pack (Data Gap DG001, flagged as Blocking — this prevents a full S1 safety assessment). Please refer to the official package insert once available.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (hyperamylasemia) has no supporting clinical trials, no literature, and no plausible mechanistic link — the evidence pack itself flags this as a likely knowledge-graph artifact rather than a genuine biological signal. Combined with the drug’s unmarketed status in Taiwan (0 licenses) and a blocking data gap on TFDA label warnings/contraindications, there is insufficient basis to advance this candidate.
To proceed, the following is needed:
- TFDA label warnings/contraindications (DG001, Blocking — required before any S1 safety screening)
- Confirmed mechanism of action data (DG002)
- If pursuing an antibacterial-indication angle instead, consider re-evaluating septicemic plague (rank 8), which has class-level mechanistic plausibility (fluoroquinolone class effect against Yersinia pestis), though sparfloxacin-specific evidence would still need to be generated
- Independent biological/literature review to confirm or rule out the hyperamylasemia signal before any further investment
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.